Actualités

Moderna stock has been on a long-term downtrend since the pandemic, and following a sharp run-up in June that saw shares gain nearly 50%, momentum appears to be fading. Moderna fell 6.4% to $74.63 on Wednesday. Shares have slid since then, losing nearly 9% over the past two sessions.

(Updates with latest market prices and developments.) US stocks were lower intraday after Preside

The iShares USA Momentum Factor ETF is up 0.3%, while the while the Invesco Momentum ETF was moving in and out of positive territory. Momentum ETFs like the iShares fund have actually added energy stocks, which were rising in the wake of the latest wave of re-escalation in the Iran war. Chip stocks, many of which were actually up on the day, are also major players in momentum ETFs.

Major US biopharmaceutical companies' performance in the second half of the year is likely to be dri

Biopharma sector's performance in H2 is expected to be driven more by company fundamentals rather th

US stocks are expected to extend losses on Wednesday after oil prices spiked following an exchange of strikes between the US and Iran that led to President Donald Trump declaring the ceasefire "over". Dow Jones futures were down 1.1%, with S&P 500 futures pointing to a 0.9% drop, while...

Arbutus expects to receive around $179 million from Moderna.

Moderna (MRNA), TG Therapeutics (TGTX), and Agios Pharmaceuticals (AGIO) will see increased scrutiny

Moderna's growth story is just beginning.

Moderna (MRNA) closed at $81.76 in the latest trading session, marking a +2.51% move from the prior day.

The Morning Bull - US Market Morning Update Monday, Jul, 6 2026 US stock futures are pointing higher this morning, with E-mini S&P 500 futures up about 0.4% and E-mini Nasdaq-100 futures up around 1.2%, as investors weigh cooling market anxiety against a packed data week. Volatility gauges like VIX futures are down roughly 2%, which means investors are currently pricing in a calmer trading day. At the same time, the ISM Services PMI, existing home sales, and the Federal Reserve meeting...

Moderna, Inc. (NASDAQ:MRNA) was among the stocks Jim Cramer commented on as he advised investors on how to take advantage of Wednesday’s market rotation. Cramer highlighted the stock’s significant gains during the year, as he said: If you look at the market’s best performers year to date, nearly all of them are either companies that […]

The stock market trades largely sideways and oil dips to pre-Iran war prices heading into the final week before Q2 earnings. Here's what to watch.

MarketBeat's weekly roundup covers a weaker June jobs report, tech sector rotation, and top analyst picks including TSLA, AVGO, PLTR, MRNA, and NEE heading into Q2 earnings season.

When a stock and the analysts covering it disagree this sharply, one of them is about to be wrong.

For most of the past three years, Jim Cramer kept his distance from Moderna, treating the biotech stock with skepticism bordering on avoidance. The Cambridge, Massachusetts, company had become synonymous with the pandemic trade, and Cramer’s enthusiasm faded as demand for Covid-era vaccines dried ...

Moderna expands beyond vaccines while Recursion bets on AI-driven drug discovery, each with distinct risks, partnerships, and financial profiles.

Moderna surges 33.5% after the company outlines plans to expand its mRNA platform beyond vaccines into oncology, autoimmune diseases and cell therapies.

Companies with more cash than debt can be financially resilient, but that doesn’t mean they’re all strong investments. Some lack leverage because they struggle to grow or generate consistent profits, making them unattractive borrowers.

The Morning Bull - US Market Morning Update Friday, Jul, 3 2026 US stock futures are slightly weaker this morning, with S&P 500 contracts edging down around 0.01%, as investors weigh softer US data against rising borrowing costs. The US private sector added 98,000 jobs in June, fewer than in May and below forecasts, which hints that hiring is cooling but unemployment near 4.3% still points to plenty of people in work. At the same time, the ISM Manufacturing PMI sits at 53.3, so factories are...

Many of this year’s hottest stocks are the biggest decliners in premarket trading Thursday after sharp drops in the previous session.

Shares of Palo Alto Networks, American Airlines Group, and Moderna climbed amid a series of positive catalysts for the companies.

Seven S&P 500 stocks have already tripled in 2026, with memory giant Sandisk far in front All are AI stocks.

Moderna shares rose nearly 20% after Science Day, driven partly by a short squeeze, while its mRNA pipeline beyond vaccines faces a multi-year path to revenue.

The list is dominated by semiconductor and computer-hardware manufacturers.

Moderna's flu vaccine may not fuel a further recovery for the hard-hit COVID-19-affected stock.

Comcast created a stir among communication services stocks with a plan to spin off its media and entertainment assets into a new publicly traded company.

Moderna hit a 52-week high after it unveiled a strategy to expand its mRNA platform beyond vaccines into oncology, autoimmune diseases and AI-driven R&D.

Moderna stock soars on positive updates during the Science Day presentation. Jefferies sees significant further upside in MRNA shares.

The Morning Bull - US Market Morning Update Monday, Jun, 29 2026 US stock futures are pointing lower this morning, with E-mini S&P 500 contracts down about 0.3% and Nasdaq-100 futures weaker by roughly 1.2%, as investors weigh solid US spending against stubborn inflation. Core PCE inflation sits at 3.4% year over year, which means the cost of living is still rising faster than the Federal Reserve would like, while real personal spending grew 0.3% and incomes rose 0.7% in May. This suggests...